Literature DB >> 20399205

MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice.

Guang Yang1, Sanghee Park, Guangwen Cao, Alexei Goltsov, Chengzhen Ren, Luan D Truong, Francesco Demayo, Timothy C Thompson.   

Abstract

Caveolin-1 (Cav-1) is a major structural protein of caveolae, specialized plasma membrane invaginations that are involved in a cell-specific fashion in diverse cell activities such as molecular transport, cell adhesion, and signal transduction. In normal adult mammals, Cav-1 expression is abundant in mesenchyme-derived cells but relatively low in epithelial parenchyma. However, epithelial Cav-1 overexpression is associated with development and/or progression of many carcinomas. In this study, we generated and characterized a transgenic mouse model of Cav-1 overexpression under the control of a mouse mammary tumor virus (MMTV) long terminal-repeat promoter, which is predominantly expressed in specific epithelial cells. The MMTVcav-1(+) transgenic mice were fertile, and females bore litters of normal size with no obvious developmental abnormalities. However, by age 11months, the MMTVcav-1(+) mice demonstrated overtly different phenotypes in multiple exocrine organs when compared with their nontransgenic MMTVcav-1(-) littermates. Cav-1 overexpression in MMTVcav-1(+) mice produced organ-specific abnormalities, including hypotrophy of mammary glandular epithelia, bronchiolar epithelial hyperplasia and atypia, mucous-cell hyperplasia in salivary glands, elongated hair follicles and dermal thickening in the skin, and reduced accumulation of enzymogen granules in pancreatic acinar cells. In addition, the MMTVcav-1(+) transgenic mice tended to have a greater incidence of malignant tumors, including lung and liver carcinomas and lymphoma, than their MMTVcav-1(-) littermates. Our results indicate that Cav-1 overexpression causes organ-specific, age-related epithelial disorders and suggest the potential for increased susceptibility to carcinogenesis. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399205      PMCID: PMC3881545          DOI: 10.1016/j.yexmp.2010.03.009

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  68 in total

1.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.

Authors:  Dolores Di Vizio; Matteo Morello; Federica Sotgia; Richard G Pestell; Michael R Freeman; Michael P Lisanti
Journal:  Cell Cycle       Date:  2009-08-27       Impact factor: 4.534

2.  Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.

Authors:  Isabelle Mercier; Mathew C Casimiro; Chenguang Wang; Anne L Rosenberg; Judy Quong; Alimatou Minkeu; Kathleen G Allen; Christiane Danilo; Federica Sotgia; Gloria Bonuccelli; Jean-François Jasmin; Huan Xu; Emily Bosco; Bruce Aronow; Agnieszka Witkiewicz; Richard G Pestell; Erik S Knudsen; Michael P Lisanti
Journal:  Cancer Biol Ther       Date:  2008-08-30       Impact factor: 4.742

3.  Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma.

Authors:  Akio Horiguchi; Tomohiko Asano; Junichi Asakuma; Takako Asano; Makoto Sumitomo; Masamichi Hayakawa
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

4.  Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions.

Authors:  Isabelle Mercier; Mathew C Casimiro; Jie Zhou; Chenguang Wang; Christopher Plymire; Kelly G Bryant; Kristin M Daumer; Federica Sotgia; Gloria Bonuccelli; Agnieszka K Witkiewicz; Justin Lin; Thai Hong Tran; Janet Milliman; Philippe G Frank; Jean-François Jasmin; Hallgeir Rui; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2009-04       Impact factor: 4.307

5.  Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression.

Authors:  Masami Watanabe; Guang Yang; Guangwen Cao; Salahaldin A Tahir; Koji Naruishi; Ken-Ichi Tabata; Elmoataz Abdel Fattah; Kartik Rajagopalan; Terry L Timme; Sanghee Park; Shinji Kurosaka; Kohei Edamura; Ryuta Tanimoto; Francesco J Demayo; Alexei A Goltsov; Timothy C Thompson
Journal:  Mol Cancer Res       Date:  2009-09-08       Impact factor: 5.852

6.  Exocrine pancreatic secretion of phospholipid, menaquinone-4, and caveolin-1 in vivo.

Authors:  Diana D H Thomas; Karen J Krzykowski; Jean A Engelke; Guy E Groblewski
Journal:  Biochem Biophys Res Commun       Date:  2004-07-02       Impact factor: 3.575

7.  Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase.

Authors:  Dolores Di Vizio; Rosalyn M Adam; Jayoung Kim; Robert Kim; Federica Sotgia; Terence Williams; Francesca Demichelis; Keith R Solomon; Massimo Loda; Mark A Rubin; Michael P Lisanti; Michael R Freeman
Journal:  Cell Cycle       Date:  2008-05-12       Impact factor: 4.534

Review 8.  The role of caveolin-1 in prostate cancer: clinical implications.

Authors:  T C Thompson; S A Tahir; L Li; M Watanabe; K Naruishi; G Yang; D Kadmon; C J Logothetis; P Troncoso; C Ren; A Goltsov; S Park
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-07-07       Impact factor: 5.554

9.  Caveolin-1 expression and stress-induced premature senescence in human intervertebral disc degeneration.

Authors:  Sarah Kathleen Heathfield; Christine Lyn Le Maitre; Judith Alison Hoyland
Journal:  Arthritis Res Ther       Date:  2008-08-05       Impact factor: 5.156

10.  Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.

Authors:  S E Elsheikh; A R Green; E A Rakha; R M Samaka; A A Ammar; D Powe; J S Reis-Filho; I O Ellis
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

View more
  5 in total

Review 1.  Caveolin-1: a critical regulator of lung injury.

Authors:  Yang Jin; Seon-Jin Lee; Richard D Minshall; Augustine M K Choi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

2.  Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.

Authors:  Shu-Ru Kuo; Salahaldin A Tahir; Sanghee Park; Timothy C Thompson; Scott Coffield; Arthur E Frankel; Jen-Sing Liu
Journal:  Hybridoma (Larchmt)       Date:  2012-04

3.  MMTV/LTR Promoter-Driven Transgenic Expression of EpCAM Leads to the Development of Large Pancreatic Islets.

Authors:  Jeffrey R Vercollone; Maarten Balzar; Sergey V Litvinov; Wendy Yang; Vincenzo Cirulli
Journal:  J Histochem Cytochem       Date:  2015-08       Impact factor: 2.479

4.  Expression of caveolin in trabecular meshwork cells and its possible implication in pathogenesis of primary open angle glaucoma.

Authors:  Irina Surgucheva; Andrei Surguchov
Journal:  Mol Vis       Date:  2011-11-09       Impact factor: 2.367

5.  Methyl-β-cyclodextrin up-regulates collagen I expression in chronologically-aged skin via its anti-caveolin-1 activity.

Authors:  Jung-Ae Lee; Da-In Choi; Jee-Young Choi; Sun-Ok Kim; Kyung-A Cho; Jee-Bum Lee; Sook-Jung Yun; Seung-Chul Lee
Journal:  Oncotarget       Date:  2015-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.